Comprehensive review of the diagnosis and treatment of biliary tract cancer 2012. PART II: Multidisciplinary management

Marsh, Robert de Wilton; Alonzo, M; Bajaj, Shailesh; Baker, Marshall S.; Elton, Eric; Farrell, Thomas A.; Gore, Richard M.; Hall, Curtis R.; Nowak, Jan A.; Roy, Hemant K.; Shaikh, Arif; Talamonti, Mark S.

doi:10.1002/jso.23027

Cited by 27 publications

(17 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The morbidity and mortality of surgical intervention to establish drainage have largely mitigated against this approach in the face of increasing evidence of the efficacy of biliary stenting. There has, however, been extensive investigation as to the optimum use of stents to palliate biliary obstruction associated with cholangiocarcinoma [2,3].…”

Section: Endoscopically Placed Stentsmentioning

confidence: 99%

See 1 more Smart Citation

The palliation of cholangiocarcinoma

Shariff

Khan²,

Westaby³

2013

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

show abstract

Section: Endoscopically Placed Stentsmentioning

confidence: 99%

“…Worldwide, cholangiocarcinoma is the second most common primary liver cancer, after hepatocellular carcinoma (HCC) [1][2][3][4]. In the United Kingdom, cholangiocarcinoma kills approximately 1500 people per year and since the 1990s, more deaths have been coded to cholangiocarcinoma than to HCC [5,6].…”

Section: Introductionmentioning

confidence: 99%

The palliation of cholangiocarcinoma

Shariff

Khan²,

Westaby³

2013

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

show abstract

“…Surgical resection, combination chemotherapy and radiotherapy have been acknowledged to improve patient prognosis as the multimodal treatment for advanced cancer (1,2). However, overall survival has remained low in advanced cancer and is a challenging obstruction to overcome (3).…”

Section: Introductionmentioning

confidence: 99%

Calreticulin is an effective immunologic adjuvant to tumor-associated antigens

Wang

Gao

Qin

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. As a key molecule involved in cell recognition, calreticulin (CRT) may be expressed on the surface of (pre-) apoptotic cells and provide the signal that is recognized by dendritic cells (DCs) or other antigen presenting cells (APCs), which results in phagocytosis. Within the APCs, tumor-associated antigens (TAAs) may be subsequently presented to T lymphocytes, which triggers a specific antitumor immune response. It has been hypothesized that CRT is able to act as the immunologic adjuvant and translocate itself and TAAs to the cell surface and induce a specific antitumor immune response. In the present study, CRT was demonstrated to translocate itself and mucin 1 (MUC1), a breast cancer antigen, to the surface of 4T1 cells and the MUC1-CRT-coated cells were able to induce apoptosis in a time-dependent manner. When DCs were infected with adenovirus containing MUC1-CRT, an increase in T cell proliferation and cytokine production was exhibited. These results suggest that CRT may act as an immunologic adjuvant with MUC1 and induce a strong immune response.

show abstract

“…3 Metal stents (bare metal mesh) are usually preferred and carry the advantage of longer duration of patency compared with plastic stents. 4 There is controversy over unilateral versus bilateral stents in unresectable hilar biliary obstruction, as only a portion of the liver will be drained with a single stent. 2 Tumor ablation combined with stenting can reduce cholestasis and improve median survival time in patients with cholangiocarcinoma.…”

Section: Introductionmentioning

confidence: 99%